Integrated Wellness
Member Login

The visual research atlas

The science.
Made clearer.

Clear explanations first. Scientific detail only when you want it. Explore a molecule, what it interacts with, what researchers measured and what they still don’t know.

Illustrated overview + interactive explanations

Education. Research. Perspective. For learning about research only. These simple maps are not medical advice or instructions for treatment. They do not tell you what to take, how much to take, or what to combine. Showing a possible biological process does not prove that it helps people.

Human outcomesHuman trials in specific groups

What changes after a cell receives a signal?

Explore how semaglutide acts on signal receivers in the body, then see why studies in people are needed to measure benefits and harms.

How strong is the evidence?

Stronger human evidence · specific uses

  1. Limited evidence
  2. Early research
  3. Human research
  4. Human outcomesCurrent category

Controlled human trials support specific outcomes in the people studied. That does not prove every claimed use, remove risks or make a treatment right for everyone.

For this research: A medicine’s actions help explain a study. They do not predict an individual’s results or replace safety advice.

An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.

CONCEPTUAL MAP / NOT TO SCALE

Select a step to explore · Use arrow keys

These are simple illustrations, not exact pictures of molecules. Arrows connect ideas; they do not prove that every step happens in people, that a treatment works, or that it is safe.

1 / 4

STEP 01 / IN PLAIN LANGUAGE

A hormone-like signal

Semaglutide acts on the same type of receiver as a hormone called GLP-1. Approved medicines containing it have specific uses and safety rules.

Based on: How the medicine interacts with the body

What this does not prove: A research vial is not the same as an approved finished medicine.

Want the scientific detail?

Semaglutide

Semaglutide is designed to act on GLP-1 receptors. Finished medications differ in formulation, label and eligible population.

Evidence context: Drug pharmacology

Important limit: Research preparations are not interchangeable with FDA-approved finished products.

Keep the distinction: A medicine’s actions help explain a study. They do not predict an individual’s results or replace safety advice.
Read the full molecule profile Follow the metabolism trail

A dated view of the research

Selected sources checked:

This date tells you when the linked sources were checked. It does not mean every new study or every part of a medicine’s safety label was reviewed. This site does not monitor changes or update itself automatically. Research and regulations can change. Follow the official source links to check for later information.

See 2 sources & what was checked

Official product database · Original approval: June 4, 2021

Drugs@FDA: Wegovy approval record

Product identity and approval history checked; use the official record for label changes. Not a complete label review.

Scientific detail is optional. Publication dates tell you when studies appeared; the source-check date tells you when these links and selected information were checked. This is a selected reading list, not a review of every study or an independent medical endorsement.

Education, not a prescription. Research summaries are not medical advice, dosing instructions, or an offer to sell. Mechanistic findings do not establish clinical effectiveness. US regulatory status is product- and indication-specific and may change. Discuss health decisions with a licensed clinician.